catechin has been researched along with Down Syndrome in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (2.94) | 29.6817 |
| 2010's | 22 (64.71) | 24.3611 |
| 2020's | 11 (32.35) | 2.80 |
| Authors | Studies |
|---|---|
| Blackwell, M; Jamal, R; LaCombe, J; Patel, R; Roper, RJ; Sloan, K; Thomas, JR; Wallace, JM | 1 |
| Dairou, J; Gu, Y; Janel, N; Kandiah, J; Moroy, G; Noll, C | 1 |
| Aldea-Perona, A; Cés, SV; Cieuta-Walti, C; Cuenca-Royo, A; Dairou, J; Dierssen, M; Durand, S; Forcano, L; Fornell, RT; García, JG; Gomis-Gonzalez, M; González, TB; González-Lamuño Leguina, D; Janel, N; Lacaille, F; Langohr, K; Lévy, M; Lirio, J; López-Vílchez, MÁ; Mircher, C; Rakic, C; Ravel, A; Roure, MR; Sacco, S; Walti, H | 1 |
| Callaerts-Vegh, Z; González-Colom, R; Llambrich, S; Martínez-Abadías, N; Roldán, J; Salassa, S; Sharpe, J; Van Bulck, V; Vande Velde, G; Wouters, J; Wouters, K | 1 |
| Dierssen, M; Martínez Cué, C | 1 |
| Cieuta-Walti, C; Dairou, J; de la Torre, R; Dierssen, M; Gu, Y; Janel, N; Moroy, G; Paul, JL; Rebillat, AS | 1 |
| Alemany-González, M; Dierssen, M; Gener, T; Nebot, P; Puig, MV; Vilademunt, M | 1 |
| Goodlett, CR; LaCombe, J; Patel, R; Roper, RJ; Stringer, M; Wallace, JM | 1 |
| Catuara-Solarz, S; De Toma, I; Dierssen, M; Ortega, M; Sabidó, E; Sierra, C | 1 |
| Albaigès, J; De La Torre, R; Dierssen, M; González, A; Gonzàlez, R; Llambrich, S; Martínez-Abadías, N; Sarlé, A; Sevillano, X; Sharpe, J; Starbuck, JM; Vande Velde, G; Wouters, J | 1 |
| Abeysekera, I; Dria, KJ; Goodlett, CR; LaCombe, J; Roper, RJ; Stancombe, K; Stewart, RJ; Stringer, M; Thomas, J; Wallace, JM | 1 |
| Jankun, J; Matthews-Brzozowska, T; Matthews-Kozanecka, M; Skrzypczak-Jankun, E; Wyganowska-Świątkowska, M | 1 |
| Chevalier, C; Créau, N; Dairou, J; Daubigney, F; Delabar, JM; Duchon, A; Gu, Y; Herault, Y; Janel, N; Nalesso, V; Souchet, B; Yu, Y | 1 |
| Almudimeegh, S; Berwick, DC; Cleverley, K; Fisher, EMC; Granno, S; Harvey, K; Heaton, G; Nagda, Z; Nixon-Abell, J; Plagnol, V; Rain, JC; Tosh, J; Tybulewicz, VLJ; Wiseman, FK; Zanda, M | 1 |
| de la Torre, R; Dierssen, M; Fitó, M; Langohr, K; Rodríguez, J; Xicota, L | 1 |
| Davis, CM; Drawbaugh, ML; Goodlett, CR; Long, R; Roper, RJ; Williams, JR | 1 |
| Benejam, B; Bizot, JC; Blehaut, H; Catuara, S; Covas, MI; Cuenca, A; De la Torre, R; de Lagran, MM; De Sola, S; Delabar, JM; Dierssen, M; Duchon, A; Farré, M; Fitó, M; Herault, Y; Janel, N; Langohr, K; Pons, M; Pujadas, M; Rodriguez, J | 1 |
| Bianchi, DW; Delabar, JM; Guedj, F | 1 |
| Brown, WT; Meeker, HC; Ramakrishna, N | 1 |
| Vacca, RA; Valenti, D | 1 |
| Djoussé, L | 1 |
| Abeysekera, I; Blazek, JD; Li, J; Roper, RJ | 1 |
| Abeysekera, I; Dria, KJ; Goodlett, CR; Roper, RJ; Stringer, M | 1 |
| Abeysekera, I; Berman, AG; Dria, KJ; Georgiadis, TM; Hammond, MA; Roper, RJ; Thomas, J; Wallace, JM | 1 |
| Contestabile, A; de Bari, L; de Rasmo, D; Henrion-Caude, A; Signorile, A; Vacca, RA; Valenti, D | 1 |
| Benejam, B; Blanco-Hinojo, L; Bléhaut, H; Catuara-Solarz, S; Cuenca-Royo, A; de la Torre, R; de Sola, S; Del Hoyo, L; Delabar, JM; Dierssen, M; Dueñas-Espín, I; Espadaler, JM; Farré, M; Fitó, M; Hernandez, G; Janel, N; Langohr, K; Principe, A; Pujol, J; Rodriguez, J; Sanchez-Benavides, G; Videla, S; Xicota, L | 1 |
| Bartesaghi, R; Ciani, E; Emili, M; Giacomini, A; Guidi, S; Rimondini, R; Sassi, M; Stagni, F; Trazzi, S | 1 |
| De Toma, I; Dierssen, M; Manubens-Gil, L; Ossowski, S | 1 |
| Braidy, N; Caccamese, S; Daglia, M; Nabavi, SM; Vacca, RA; Valenti, D | 1 |
| Blazek, JD; Ghoneima, A; Harrington, E; Kula, K; McElyea, SD; Roper, RJ; Starbuck, JM; Tumbleson-Brink, DM | 1 |
| Delabar, JM | 1 |
| Dunckley, T; Gokhale, V; Hulme, C; Medda, F; Smith, B | 1 |
| de Bari, L; De Rasmo, D; Granese, B; Papa, S; Rossi, L; Scala, I; Signorile, A; Vacca, RA; Valenti, D | 1 |
| Adayev, T; Chen-Hwang, MC; Hwang, YW; Murakami, N; Wegiel, J | 1 |
8 review(s) available for catechin and Down Syndrome
| Article | Year |
|---|---|
Catechins as a Potential Dietary Supplementation in Prevention of Comorbidities Linked with Down Syndrome.
Topics: Catechin; Comorbidity; Dietary Supplements; Down Syndrome; Humans; Polyphenols | 2022 |
Plasticity as a therapeutic target for improving cognition and behavior in Down syndrome.
Topics: Animals; Antioxidants; Brain; Catechin; Down Syndrome; Humans; Neuronal Plasticity; Social Environment | 2020 |
Can EGCG Alleviate Symptoms of Down Syndrome by Altering Proteolytic Activity?
Topics: Animals; Biomarkers; Catechin; Down Syndrome; Humans; Matrix Metalloproteinase Inhibitors; Metalloendopeptidases; Methylation; Proteolysis; Signal Transduction; Tissue Plasminogen Activator | 2018 |
Prenatal treatment of Down syndrome: a reality?
Topics: Animals; Animals, Newborn; Apigenin; Catechin; Choline; Disease Models, Animal; Down Syndrome; Dyrk Kinases; Female; Fluoxetine; Humans; Mice; Mice, Transgenic; Molecular Targeted Therapy; Neural Stem Cells; Neurogenesis; Neuroprotective Agents; Oxidative Stress; Pregnancy; Prenatal Care; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Receptors, GABA; Receptors, N-Methyl-D-Aspartate; Signal Transduction; Stem Cell Transplantation | 2014 |
Where Environment Meets Cognition: A Focus on Two Developmental Intellectual Disability Disorders.
Topics: Antioxidants; Catechin; Cognition; DNA Methylation; Down Syndrome; Epigenesis, Genetic; Fragile X Syndrome; Gene-Environment Interaction; Genetic Therapy; Humans; Intellectual Disability; Protein Interaction Domains and Motifs | 2016 |
Plant polyphenols as natural drugs for the management of Down syndrome and related disorders.
Topics: Biological Products; Catechin; Down Syndrome; Humans; Mitochondria; Polyphenols | 2016 |
[New perspectives on molecular and genic therapies in Down syndrome].
Topics: Animals; Catechin; Chromosomes, Human, Pair 21; Disease Models, Animal; Down Syndrome; Droxidopa; Drug Delivery Systems; Fluoxetine; Forecasting; Gene Expression Regulation; Genetic Association Studies; Genetic Therapy; Hedgehog Proteins; Humans; Memantine; Mice; Mice, Transgenic; Models, Genetic; Neuronal Plasticity; Neurotransmitter Agents; Pentylenetetrazole; Phenotype; Signal Transduction | 2010 |
Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?
Topics: Alzheimer Disease; Animals; Anthraquinones; Biomedical Research; Carbolines; Catechin; Chromosomes, Human, Pair 21; Coumarins; Down Syndrome; Drug Design; Dyrk Kinases; Humans; Mice; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; tau Proteins | 2012 |
4 trial(s) available for catechin and Down Syndrome
| Article | Year |
|---|---|
Safety and preliminary efficacy on cognitive performance and adaptive functionality of epigallocatechin gallate (EGCG) in children with Down syndrome. A randomized phase Ib clinical trial (PERSEUS study).
Topics: Catechin; Child; Cognition; Dietary Supplements; Double-Blind Method; Down Syndrome; Female; Humans; Male | 2022 |
Effect of epigallocatechin gallate on the body composition and lipid profile of down syndrome individuals: Implications for clinical management.
Topics: Adolescent; Adult; Antioxidants; Body Composition; Body Mass Index; Catechin; Cohort Studies; Double-Blind Method; Down Syndrome; Electric Impedance; Female; Humans; Lipids; Male; Sex Factors; Young Adult | 2020 |
Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.
Topics: Adolescent; Adult; Animals; Biomarkers; Catechin; Chromosomes, Human, Pair 16; Cognition; Disease Models, Animal; Double-Blind Method; Down Syndrome; Dyrk Kinases; Female; Gene Expression Regulation; Hippocampus; Humans; Male; Mice; Mice, Transgenic; Mosaicism; Phosphorylation; Pilot Projects; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Trisomy; Young Adult | 2014 |
Safety and efficacy of cognitive training plus epigallocatechin-3-gallate in young adults with Down's syndrome (TESDAD): a double-blind, randomised, placebo-controlled, phase 2 trial.
Topics: Adaptation, Psychological; Adult; Catechin; Cholesterol; Cognition Disorders; Cognitive Behavioral Therapy; Double-Blind Method; Down Syndrome; Female; Follow-Up Studies; Homocysteine; Humans; Inhibition, Psychological; Male; Neuroprotective Agents; Recognition, Psychology; Retrospective Studies; Spain; Treatment Outcome; Young Adult | 2016 |
22 other study(ies) available for catechin and Down Syndrome
| Article | Year |
|---|---|
Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models.
Topics: Animals; Catechin; Down Syndrome; Drug Administration Schedule; Dyrk Kinases; Female; Male; Mice; Muscle, Skeletal; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases | 2022 |
Green Tea Catechins Modulate Skeletal Development with Effects Dependent on Dose, Time, and Structure in a down Syndrome Mouse Model.
Topics: Animals; Antioxidants; Catechin; Disease Models, Animal; Down Syndrome; Mice; Plant Extracts; Tea | 2022 |
Molecular Rescue of Dyrk1A Overexpression Alterations in Mice with Fontup
Topics: Animals; Antioxidants; Biological Availability; Biomarkers; Blood-Brain Barrier; Brain; Catechin; Dietary Supplements; Down Syndrome; Dyrk Kinases; Liver; Mice; Mice, Inbred C57BL; Microscopy, Electron, Scanning; Molecular Docking Simulation; Neuroprotective Agents; Polyphenols; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Tea; Up-Regulation | 2020 |
Prefrontal-hippocampal functional connectivity encodes recognition memory and is impaired in intellectual disability.
Topics: Animals; Catechin; Disease Models, Animal; Down Syndrome; Executive Function; Female; Hippocampus; Male; Mice; Mice, Inbred C57BL; Nerve Net; Neuroprotective Agents; Prefrontal Cortex; Recognition, Psychology | 2020 |
Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice.
Topics: Administration, Oral; Animals; Body Weight; Cancellous Bone; Catechin; Disease Models, Animal; Down Syndrome; Femur; Maze Learning; Mice; Treatment Outcome; X-Ray Microtomography | 2020 |
Re-establishment of the epigenetic state and rescue of kinome deregulation in Ts65Dn mice upon treatment with green tea extract and environmental enrichment.
Topics: Animals; Camellia sinensis; Catechin; Chromatography, Liquid; Cognition; Disease Models, Animal; Down Syndrome; Epigenesis, Genetic; Hippocampus; Mice; Mice, Transgenic; Phosphorylation; Plant Extracts; Protein Interaction Maps; Proteomics; Tandem Mass Spectrometry | 2020 |
Green tea extracts containing epigallocatechin-3-gallate modulate facial development in Down syndrome.
Topics: Adolescent; Animals; Catechin; Child; Child, Preschool; Dietary Supplements; Disease Models, Animal; Down Syndrome; Face; Female; Humans; Infant; Male; Mice; Plant Extracts; Tea | 2021 |
Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
Topics: Administration, Oral; Animals; Brain; Catechin; Cognition; Disease Models, Animal; Down Syndrome; Dyrk Kinases; Femur; Male; Maze Learning; Mice, Inbred C3H; Mice, Transgenic; Motor Activity; Phenotype; Protease Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Random Allocation; Recognition, Psychology; Treatment Failure | 2017 |
Prenatal treatment with EGCG enriched green tea extract rescues GAD67 related developmental and cognitive defects in Down syndrome mouse models.
Topics: Animals; Brain; Catechin; Cognition; Disease Models, Animal; Down Syndrome; Dyrk Kinases; Female; Glutamate Decarboxylase; Interneurons; Maternal-Fetal Exchange; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pregnancy; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Tea | 2019 |
Downregulated Wnt/β-catenin signalling in the Down syndrome hippocampus.
Topics: Adaptor Proteins, Signal Transducing; Aged; Alzheimer Disease; Animals; Axin Protein; Catechin; Chromosomes, Human, Pair 21; Disease Models, Animal; Down Syndrome; Down-Regulation; Dyrk Kinases; Female; HEK293 Cells; HeLa Cells; Hippocampus; Humans; Male; Mice; Middle Aged; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; RNA-Seq; Wnt Signaling Pathway | 2019 |
Usage of and attitudes about green tea extract and Epigallocathechin-3-gallate (EGCG) as a therapy in individuals with Down syndrome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Attitude; Caregivers; Catechin; Cross-Sectional Studies; Dietary Supplements; Down Syndrome; Female; Humans; Male; Middle Aged; Plant Extracts; Tea; Young Adult | 2019 |
Novel Epigenetic Regulation of Alpha-Synuclein Expression in Down Syndrome.
Topics: alpha-Synuclein; Animals; Catechin; Disease Models, Animal; DNA Methylation; Down Syndrome; Epigenesis, Genetic; Mice; Promoter Regions, Genetic | 2016 |
Green tea EGCG plus fish oil omega-3 dietary supplements rescue mitochondrial dysfunctions and are safe in a Down's syndrome child.
Topics: Catechin; Child; Dietary Supplements; Down Syndrome; Fatty Acids, Omega-3; Fish Oils; Humans; Mitochondria; Tea | 2015 |
Reply: Green tea EGCG plus fish oil omega-3 dietary supplements rescue mitochondrial dysfunctions and are safe in a Down's syndrome child.
Topics: Catechin; Down Syndrome; Fatty Acids, Omega-3; Fish Oils; Humans; Mitochondria | 2015 |
Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice using genetic and therapeutic modulation of trisomic Dyrk1a.
Topics: Animals; Bone Diseases; Catechin; Disease Models, Animal; Down Syndrome; Dyrk Kinases; Gene Dosage; Male; Mice; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases | 2015 |
Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model.
Topics: Aging; Animals; Behavior, Animal; Brain Chemistry; Catechin; Cognition Disorders; Down Syndrome; Dyrk Kinases; Female; Growth; Learning; Maze Learning; Mice; Mice, Transgenic; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Recognition, Psychology | 2015 |
Differential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model.
Topics: Absorptiometry, Photon; Animals; Bone and Bones; Catechin; Dietary Supplements; Disease Models, Animal; Down Syndrome; Female; Femur; Male; Mice, Inbred C57BL; Mice, Mutant Strains; X-Ray Microtomography | 2016 |
The polyphenols resveratrol and epigallocatechin-3-gallate restore the severe impairment of mitochondria in hippocampal progenitor cells from a Down syndrome mouse model.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinase Kinases; Animals; Antioxidants; Catechin; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Down Syndrome; Female; Hippocampus; Male; Mice; Mitochondria; Neural Stem Cells; Neurogenesis; Neuroprotective Agents; Protein Kinases; Resveratrol | 2016 |
Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome.
Topics: Animals; Catechin; Cognition; Disease Models, Animal; Down Syndrome; Female; Hippocampus; Male; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Transgenic; Neocortex; Neural Pathways; Neurogenesis; Neuroprotective Agents; Synapses; Time Factors | 2016 |
Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.
Topics: Animals; Catechin; Craniofacial Abnormalities; Disease Models, Animal; Down Syndrome; Dyrk Kinases; Female; Gene Dosage; Mice; Phenotype; Phosphorylation; Pregnancy; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases | 2016 |
Epigallocatechin-3-gallate prevents oxidative phosphorylation deficit and promotes mitochondrial biogenesis in human cells from subjects with Down's syndrome.
Topics: Adenosine Triphosphate; Catechin; Cells, Cultured; Chromosomes, Human, Pair 21; Down Syndrome; Fibroblasts; Heat-Shock Proteins; Humans; Mitochondria; Oxidative Phosphorylation; Oxidative Stress; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Reactive Oxygen Species; Signal Transduction; Sirtuin 1; Tea; Transcription Factors; Trisomy | 2013 |
Kinetic properties of a MNB/DYRK1A mutant suitable for the elucidation of biochemical pathways.
Topics: Adenosine Triphosphate; Amino Acid Substitution; Animals; Antioxidants; Catechin; Down Syndrome; Drug Resistance; Dyrk Kinases; Kinetics; Mice; Mutation, Missense; NIH 3T3 Cells; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases | 2006 |